Observational study / 2017
Genetically predicted coffee intake was not linked to prostate cancer risk, grade, or mortality, but showed higher odds of nonlocalized disease.
Researchers conducted a Mendelian randomization study using two caffeine-associated genetic variants (rs4410790 and rs2472297) as proxies for coffee intake in 46,687 men. A combined genetic risk score showed no clear evidence of association with prostate cancer risk (OR: 1.01, 95% CI: 0.98, 1.03) or high-grade versus low-grade disease (OR: 1.01, 95% CI: 0.97, 1.04). However, there was some evidence linking the score to higher odds of nonlocalized versus localized disease (OR: 1.03, 95% CI: 1.01, 1.06). Among men with prostate cancer, the genetic score showed no clear association with all-cause mortality (HR: 1.00, 95% CI: 0.97, 1.04) or prostate cancer-specific mortality (HR: 1.03, 95% CI: 0.98, 1.08).
Shows an association, not proof of cause and effect.
- Study type
- Mendelian randomization study
- Who was studied
- 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium
- What was measured
- Prostate cancer risk, disease stage, disease grade, all-cause mortality, and prostate cancer-specific mortality
THE PAPER
Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis.
Taylor AE, Martin RM, Geybels MS, Stanford JL, Shui I, Eeles R, Easton D, Kote-Jarai Z, Amin Al Olama A, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Neal D, Pashayan N, Khaw KT, Blot W, Thibodeau S, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H, PRACTICAL Consortium, Donovan J, Munafò MR. Int J Cancer, 2017.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.